NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Myeloma & Lymphoma
NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
NCT05338775: Phase 1: Talquetamab and Teclistamab Each with (PD-1) Inhibitor RRMM - (TRIMM-3)
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05243797: Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T
NCT05218603: Bortezomib Plus Daratumumab (V-Dara) After Induction With VMP-Dara - NDMM -TIE Myeloma
NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia
NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Cilta-Cel CART
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma
NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant
NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function
NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)
NCT05064358: Phase 2 - Alternative Dosing Regimens of Belantamab Mafodotin RRMM - (DREAMM 14)
NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma